88 related articles for article (PubMed ID: 25813652)
1. [Is PON1 a factor of cardiovascular risk in type 2 diabetes?].
Triki S; Fekih O; Hellara I; Neffati F; Douki W; Ben Hamda K; Maatouk F; Najjar MF
Ann Cardiol Angeiol (Paris); 2016 Apr; 65(2):81-6. PubMed ID: 25813652
[TBL] [Abstract][Full Text] [Related]
2. Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus.
Singh S; Venketesh S; Verma JS; Verma M; Lellamma CO; Goel RC
Indian J Med Res; 2007 Jun; 125(6):783-7. PubMed ID: 17704557
[TBL] [Abstract][Full Text] [Related]
3. Low serum paraoxonase1 activity levels predict coronary artery disease severity.
Sun T; Hu J; Yin Z; Xu Z; Zhang L; Fan L; Zhuo Y; Wang C
Oncotarget; 2017 Mar; 8(12):19443-19454. PubMed ID: 28038449
[TBL] [Abstract][Full Text] [Related]
4. [Is paraoxonase 1 a marker of cardiovascular risk in youth with type 1 diabetes? (Study about 109 cases)].
Fekih O; Triki S; Hellara I; Neffati F; Chouchane S; Neji Gueddiche M; Fadhel Najjar M
Presse Med; 2015 May; 44(5):e185-90. PubMed ID: 25769648
[TBL] [Abstract][Full Text] [Related]
5. The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose.
Lu C; Gao Y; Zhou H; Tian H
Coron Artery Dis; 2008 Dec; 19(8):565-73. PubMed ID: 19005291
[TBL] [Abstract][Full Text] [Related]
6. Low serum PON1 activity: an independent risk factor for coronary artery disease in North-West Indian type 2 diabetics.
Gupta N; Binu KB; Singh S; Maturu NV; Sharma YP; Bhansali A; Gill KD
Gene; 2012 Apr; 498(1):13-9. PubMed ID: 22333293
[TBL] [Abstract][Full Text] [Related]
7. Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease.
Ding J; Chen Q; Zhuang X; Feng Z; Xu L; Chen F
Med Sci Monit; 2014 Nov; 20():2421-9. PubMed ID: 25420483
[TBL] [Abstract][Full Text] [Related]
8. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications.
Bansal S; Chawla D; Siddarth M; Banerjee BD; Madhu SV; Tripathi AK
Clin Biochem; 2013 Jan; 46(1-2):109-14. PubMed ID: 23103709
[TBL] [Abstract][Full Text] [Related]
9. Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitus.
Shen Y; Ding FH; Sun JT; Pu LJ; Zhang RY; Zhang Q; Chen QJ; Shen WF; Lu L
Cardiovasc Diabetol; 2015 May; 14():52. PubMed ID: 25964115
[TBL] [Abstract][Full Text] [Related]
10. A case control study on HDL associated PON1 enzyme level in Northern Indian type 2 diabetes mellitus patients.
Wamique M; Ali W; Reddy DH; Vishwakarma P; Waseem M
Diabetes Metab Syndr; 2018 Nov; 12(6):843-847. PubMed ID: 29843993
[TBL] [Abstract][Full Text] [Related]
11. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population.
Gupta N; Binukumar BK; Singh S; Sunkaria A; Kandimalla R; Bhansali A; Gill KD
Gene; 2011 Nov; 487(1):88-95. PubMed ID: 21803130
[TBL] [Abstract][Full Text] [Related]
12. Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients.
Boemi M; Sirolla C; Testa R; Cenerelli S; Fumelli P; James RW
Diabet Med; 2004 May; 21(5):423-7. PubMed ID: 15089785
[TBL] [Abstract][Full Text] [Related]
13. Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes.
Connelly PW; Zinman B; Maguire GF; Mamakeesick M; Harris SB; Hegele RA; Retnakaran R; Hanley AJ
J Lipid Res; 2009 Jun; 50(6):1216-22. PubMed ID: 19151417
[TBL] [Abstract][Full Text] [Related]
14. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease.
Mackness B; Hine D; McElduff P; Mackness M
Atherosclerosis; 2006 Jun; 186(2):396-401. PubMed ID: 16140307
[TBL] [Abstract][Full Text] [Related]
15. Phenotypes and concentration of PON1 in cardiovascular disease: The role of nutrient intake.
Ponce-Ruiz N; Murillo-González FE; Rojas-García AE; Bernal Hernández YY; Mackness M; Ponce-Gallegos J; Barrón-Vivanco BS; Hernández-Ochoa I; González-Arias CA; Ortega Cervantes L; Cardoso-Saldaña G; Medina-Díaz IM
Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):40-48. PubMed ID: 31757567
[TBL] [Abstract][Full Text] [Related]
16. Paraoxonase, oxidized low density lipoprotein, monocyte chemoattractant protein-1 and adhesion molecules are associated with macrovascular complications in patients with type 2 diabetes mellitus.
Sozer V; Himmetoglu S; Korkmaz GG; Kaya S; Aydin S; Yumuk V; Hatemi H; Uzun H
Minerva Med; 2014 Jun; 105(3):237-44. PubMed ID: 24988089
[TBL] [Abstract][Full Text] [Related]
17. Association of RAGE gene polymorphism with circulating AGEs level and paraoxonase activity in relation to macro-vascular complications in Indian type 2 diabetes mellitus patients.
Bansal S; Chawla D; Banerjee BD; Madhu SV; Tripathi AK
Gene; 2013 Sep; 526(2):325-30. PubMed ID: 23721855
[TBL] [Abstract][Full Text] [Related]
18. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
19. Serum paraoxonase 1 activity in women with metabolic syndrome.
Yilmaz H; Sayar N; Yilmaz M; Gurkan U; Sesal C; Tosu R; Cakmak N; Erer B; Oz D; Ciloglu F; Bolca O
Kardiol Pol; 2010 Nov; 68(11):1219-24. PubMed ID: 21108196
[TBL] [Abstract][Full Text] [Related]
20. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease.
Haraguchi Y; Toh R; Hasokawa M; Nakajima H; Honjo T; Otsui K; Mori K; Miyamoto-Sasaki M; Shinohara M; Nishimura K; Ishida T; Hirata K
Atherosclerosis; 2014 Jun; 234(2):288-94. PubMed ID: 24704632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
